Researchers say study results provide a clear rationale for developing therapies that target LCN2 in lung cancer patients.
Jim Tananbaum, MD, Foresite Capital’s founder and CEO, and Michael Rome, PhD, the managing director who leads the firm’s therapeutics investing practice, discuss the firm’s approach to nurturing ...
A UCLA study found that macrophages rely on interferon gamma signaling from past infections to preserve innate defenses.
SPT Labtech, BellBrook Labs Automate Screening for VPS4B ATPase Inhibitors for Cancer Drug Discovery
According to data shared during SLAS, the platform was instrumental in helping BellBrook Labs identify 13 novel inhibitors of the protein.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results